Novartis Licenses MorphoSys/Galapagos Atopic Dermatitis Candidate MOR106 for $1.1B+

Novartis is licensing the Phase II atopic dermatitis candidate MOR106 from MorphoSys and Galapagos, which partnered to create the monoclonal antibody, through a global exclusive licensing deal that could generate more than $1.1 billion for the pharma giant.MOR106 is a fully human, IgG1 monoclonal antibody designed to target interleukin 17C (IL-17C). MOR106 is under study in the Phase II IGUANA trial ( NCT03568071 ) assessing the candidate’s efficacy, safety, tolerability, and pharmacokinet